Literature DB >> 23979975

Association between FAS 1377G>A polymorphism and breast cancer susceptibility: a meta-analysis.

Kai Li1, Wusheng Li, Huawei Zou, Li Zhao.   

Abstract

Published studies on the association between FAS 1377G>A polymorphism and breast cancer susceptibility were inconclusive. To derive a more precise assessment of the association, a meta-analysis of published studies was performed. PubMed, Embase, and Web of Science were searched for eligible studies on the association between FAS 1377G>A polymorphism and breast cancer susceptibility. Five studies with a total of 2,905 cases and 3,090 controls were included into the meta-analysis. Overall, FAS 1377G>A polymorphism was significantly associated with increased susceptibility to breast cancer (for AA versus GG: odds ratio (OR) = 1.39, 95% confidence interval (95% CI) 1.12-1.72, P = 0.003; for AA/GA versus GG: OR = 1.18, 95% CI 1.06-1.32, P = 0.004; for AA versus GG/GA: OR = 1.28, 95% CI 1.05-1.56, P = 0.015). Subgroup analysis by ethnicity found that FAS 1377G>A polymorphism was significantly associated with increased susceptibility to breast cancer in Asians (for AA versus GG: OR = 1.48, 95% CI 1.16-1.89, P = 0.001; for AA/GA versus GG: OR = 1.24, 95% CI 1.06-1.46, P = 0.008; for AA versus GG/GA: OR = 1.35, 95% CI 1.08-1.69, P = 0.008), but the association was not found in Caucasians. Therefore, the findings of the meta-analysis suggest that FAS 1377G>A polymorphism is significantly associated with increased susceptibility to breast cancer in Asians.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23979975     DOI: 10.1007/s13277-013-1048-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  26 in total

1.  Re: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma.

Authors:  Peter Krippl; Uwe Langsenlehner; Wilfried Renner; Herwig Köppel; Hellmut Samonigg
Journal:  J Natl Cancer Inst       Date:  2004-10-06       Impact factor: 13.506

2.  FAS -1,377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls.

Authors:  Li-Xin Qiu; Jian Shi; Hui Yuan; Xin Jiang; Kai Xue; Hai-Feng Pan; Jin Li; Ming-Hua Zheng
Journal:  Hum Genet       Date:  2009-02-19       Impact factor: 4.132

Review 3.  Death receptor signal transducers: nodes of coordination in immune signaling networks.

Authors:  Nicholas S Wilson; Vishva Dixit; Avi Ashkenazi
Journal:  Nat Immunol       Date:  2009-03-19       Impact factor: 25.606

4.  FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies.

Authors:  Zhizhong Zhang; Hengchuan Xue; Weida Gong; Meilin Wang; Lin Yuan; Suping Han; Zhengdong Zhang
Journal:  Carcinogenesis       Date:  2009-01-23       Impact factor: 4.944

Review 5.  Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review.

Authors:  Linda J M Oostendorp; Peep F M Stalmeier; A Rogier T Donders; Winette T A van der Graaf; Petronella B Ottevanger
Journal:  Lancet Oncol       Date:  2011-05-27       Impact factor: 41.316

Review 6.  Measuring and modeling apoptosis in single cells.

Authors:  Sabrina L Spencer; Peter K Sorger
Journal:  Cell       Date:  2011-03-18       Impact factor: 41.582

Review 7.  Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress.

Authors:  Ira Tabas; David Ron
Journal:  Nat Cell Biol       Date:  2011-03       Impact factor: 28.824

8.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

Review 9.  Gene expression profiling in breast cancer: classification, prognostication, and prediction.

Authors:  Jorge S Reis-Filho; Lajos Pusztai
Journal:  Lancet       Date:  2011-11-19       Impact factor: 79.321

10.  Estimating single nucleotide polymorphism associations using pedigree data: applications to breast cancer.

Authors:  D R Barnes; D Barrowdale; J Beesley; X Chen; P A James; J L Hopper; D Goldgar; G Chenevix-Trench; A C Antoniou; G Mitchell
Journal:  Br J Cancer       Date:  2013-06-11       Impact factor: 7.640

View more
  2 in total

1.  Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently.

Authors:  Sateesh Reddy Nallapalle; Sarika Daripally; V T S Vidudala Prasad
Journal:  Tumour Biol       Date:  2014-12-04

2.  Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia.

Authors:  Prajitha Mohandas Edathara; Manjula Gorre; Sailaja Kagita; Sugunakar Vuree; Anuradha Cingeetham; Santhoshi Rani Nanchari; Phanni Bhushann Meka; Sandhya Annamaneni; Raghunadha Rao Digumarthi; Vishnupriya Satti
Journal:  Tumour Biol       Date:  2015-11-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.